Advertisement

Der Internist

, Volume 60, Issue 2, pp 149–160 | Cite as

Interventionelle Angiologie

Endovaskuläre Behandlung der chronischen und akuten Extremitätenischämie
  • Sabine SteinerEmail author
  • Andrej Schmidt
  • Dierk Scheinert
CME
  • 167 Downloads

Zusammenfassung

Die Möglichkeiten einer endovaskulären Behandlung der chronischen und akuten Extremitätenischämie haben sich in den letzten 20 Jahren durch die Entwicklung neuer Technologien und Verfahrenstechniken deutlich erweitert. Die meisten Patienten mit symptomatischer peripherer arterieller Verschlusskrankheit können heute im Sinne einer Endovascular-first-Strategie minimal-invasiv als Alternative zur klassischen Bypasschirurgie behandelt werden. Ballonangioplastie und Stentimplantation sind Eckpfeiler der endovaskulären Behandlungstechniken. Bei komplexen Rekonstruktionen der Beckengefäße kommen häufig gecoverte Stentprothesen zum Einsatz. Die Offenheitsrate nach femoropoplitealen Interventionen wurde durch die Verwendung von medikamentenfreisetzenden Ballons und Stents deutlich erhöht. Dank verbesserter Materialien und neuer Zugangstechniken können mehr und komplexere infrapopliteale Stenosen und Verschlüsse erfolgreich eröffnet werden.

Schlüsselwörter

Periphere arterielle Verschlusskrankheit Claudicatio intermittens Kritische Extremitätenischämie Angioplastie Stents 

Interventional angiology

Endovascular treatment of chronic and acute limb ischemia

Abstract

The development of new technologies and techniques has significantly advanced the field of endovascular peripheral interventions for chronic and acute limb ischemia over the last 20 years. Nowadays, the majority of patients with symptomatic peripheral arterial occlusive disease can be treated percutaneously using an endovascular first approach as a minimally invasive alternative to classical bypass surgery. Balloon angioplasty and stent implantation are the mainstays of endovascular interventions. For reconstruction of complex aortoiliac occlusions covered stents are frequently used. Patency rates after femoropopliteal interventions have been improved by the introduction of drug-eluting balloon and stent technologies. Advances in material and access techniques now enable the successful endovascular treatment of more complex infrapopliteal stenoses and occlusions.

Keywords

Peripheral arterial disease Intermittent claudication Ischemia, limb, critical Angioplasty Stents 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

S. Steiner, A. Schmidt und D. Scheinert geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Criqui MH, Aboyans V (2015) Epidemiology of peripheral artery disease. Circ Res 116(9):1509–1526CrossRefGoogle Scholar
  2. 2.
    Lawall H et al (2016) S3-Leitlinie PAVK - Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Vasa 45(Suppl 95):1–100Google Scholar
  3. 3.
    Hageman D et al (2018) Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.cd005263.pub4 CrossRefPubMedGoogle Scholar
  4. 4.
    Norgren L et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45(Suppl S):S5–S67CrossRefGoogle Scholar
  5. 5.
    The TASC Steering Committee et al (2015) An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). Vasc Med 20(5):465–478CrossRefGoogle Scholar
  6. 6.
    Dake MD et al (2016) Durable clinical effectiveness with Paclitaxel-eluting stents in the femoropopliteal artery: 5‑year results of the Zilver PTX randomized trial. Circulation 133(15):1472–1483 (discussion 1483)CrossRefGoogle Scholar
  7. 7.
    Gray WA et al (2018) A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 392(10157):1541–1551.  https://doi.org/10.1016/s0140-6736(18)32262-1 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kayssi A et al (2016) Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.cd011319.pub2 CrossRefPubMedGoogle Scholar
  9. 9.
    Jongkind V et al (2010) A systematic review of endovascular treatment of extensive aortoiliac occlusive disease. J Vasc Surg 52(5):1376–1383CrossRefGoogle Scholar
  10. 10.
    Bekken JA, Jongsma H, Fioole B (2018) The use of covered stents in aortoiliac obstructions: a systematic review and meta-analysis. J Cardiovasc Surg (Torino) 59(1):14–25Google Scholar
  11. 11.
    Taeymans K et al (2018) Three-year outcome of the covered endovascular reconstruction of the aortic bifurcation technique for aortoiliac occlusive disease. J Vasc Surg 67(5):1438–1447CrossRefGoogle Scholar
  12. 12.
    Scheinert D et al (2005) Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 45(2):312–315CrossRefGoogle Scholar
  13. 13.
    Muller-Hulsbeck S et al (2017) Long-term results from the MAJESTIC trial of the Eluvia Paclitaxel-eluting stent for femoropopliteal treatment: 3‑year follow-up. Cardiovasc Intervent Radiol 40(12):1832–1838CrossRefGoogle Scholar
  14. 14.
    Werner M et al (2014) Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention 10(7):861–868CrossRefGoogle Scholar
  15. 15.
    Goueffic Y et al (2017) Stenting or surgery for de novo common femoral artery stenosis. JACC Cardiovasc Interv 10(13):1344–1354CrossRefGoogle Scholar
  16. 16.
    Varcoe RL (2013) Drug eluting stents in the treatment of below the knee arterial occlusive disease. J Cardiovasc Surg (Torino) 54(3):313–325Google Scholar
  17. 17.
    Zeller T et al (2017) Directional atherectomy followed by a Paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR Study. Circ Cardiovasc Interv.  https://doi.org/10.1161/circinterventions.116.004848 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hussain MA et al (2018) Antithrombotic therapy for peripheral artery disease: recent advances. J Am Coll Cardiol 71(21):2450–2467CrossRefGoogle Scholar
  19. 19.
    Aboyans V et al (2018) 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 39(9):763–816CrossRefGoogle Scholar
  20. 20.
    Eikelboom JW et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319–1330CrossRefGoogle Scholar
  21. 21.
    Anand SS et al (2018) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391(10117):219–229CrossRefGoogle Scholar
  22. 22.
    Rutherford RB et al (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26(3):517–538CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Sabine Steiner
    • 1
    Email author
  • Andrej Schmidt
    • 1
  • Dierk Scheinert
    • 1
  1. 1.Klinik und Poliklinik für Angiologie, Department für Innere Medizin, Neurologie und DermatologieUniversitätsklinikum Leipzig (AöR)LeipzigDeutschland

Personalised recommendations